newsfilter
← Latest News
GlobeNewswire·

Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares

QNTM
  • Quantum BioPharma Ltd. held its annual general & special meeting on November 10, 2026, in Toronto, & closed a non-brokered private placement of 26 Class A Multiple Voting Shares on November 9, 2026.
  • Five nominees—Anthony Durkacz, Zeeshan Saeed, Adnan Bashir, Michael (Zappy) Zapolin, & Dr. Eric Hoskins—were re-elected as directors with over 97% of votes cast in their favor.
  • Shareholders approved the re-appointment of MNP LLP as auditor, an omnibus equity incentive plan, a consolidation resolution allowing up to a 10-for-1 share consolidation, & a resolution authorizing a potential name change.
  • The MVS Issuance Resolution passed with 65.764% support from disinterested Class B shareholders, authorizing the board to issue additional Class A shares to maintain their voting power at up to 70%.
  • The private placement issued 26 Class A Multiple Voting Shares at C$3.11 per share, generating C$80.86 in gross proceeds for general working capital purposes.
  • The 26 shares were issued to close the remaining portion of the 2025 Authority before its expiration, with all securities subject to a statutory hold period expiring March 10, 2027.
  • Post-offering, the 68 outstanding Class A Multiple Voting Shares represent approximately 68.22% of the company's total voting power, up from 57.01% prior to the transaction.
  • Xorax Family Trust & Fortius Research and Trading Corp., affiliated with insiders Zeeshan Saeed & Anthony Durkacz, each acquired 13 Class A Multiple Voting Shares for C$40.43 each under a related party transaction exempt from formal valuation requirements.
  • Immediately following the offering, Xorax holds approximately 34.98% of voting power (including joint actors) & Fortius holds approximately 34.66% of voting power (including joint actors), with both parties required to file early warning reports.
Company
Quantum BioPharma
Keywords
Nasdaq:QNTM, Quantum BioPharma